Type 1 diabetes: Medications

Treatment with the SGLT2 inhibitor dapagliflozin produces acute increases in renal oxygenation in people with type 1 diabetes and albuminuria, say researchers.

A 6-month course of treatment with the tyrosine kinase inhibitor imatinib may slow the decline in beta-cell function in people with newly diagnosed type 1 diabetes, but the effect is not sustained in the longer term, phase 2 study findings indicate.

Add-on treatment with the glucagon receptor antagonist volagidemab may improve glycemic control in people with type 1 diabetes, suggest phase 2 study results.

A co-formulation of pramlintide and a prandial insulin offers improved postprandial glucose control and weight loss, without an increased number of injections, show the results of a small crossover trial.

Use of insulin degludec is associated with a reduced risk for recurrent nocturnal hypoglycemia as measured by hourly plasma glucose among adults with type 1 diabetes, suggest findings from the overnight substudy of the HypoDeg trial.

The Omnipod 5 tubeless automated insulin delivery system improves glycemic outcomes of very young children with type 1 diabetes and the sleep of their caregivers, report researchers.

The results of two studies published in JAMA indicate that real-time continuous glucose monitoring benefits people with type 1 or type 2 diabetes on a range of insulin regimens and from a wide variety of backgrounds.

Dasiglucagon, a next-generation glucagon analog in a ready-to-use formulation, rapidly restores plasma glucose levels following severe hypoglycemia in children and adolescents with type 1 diabetes, show findings from a phase 3 trial.

Phase 2 study results suggest that add-on treatment with an anti-IL-21 antibody plus liraglutide could preserve endogenous insulin secretion in people with recent-onset type 1 diabetes.

Prolonged follow-up of high-risk people treated with teplizumab to prevent progression to type 1 diabetes shows a lasting beneficial effect on beta-cell function, say researchers.

Early findings suggest a novel molecule that selectively targets hepatic glucokinase may improve glucose control and reduce acute complication risk in people with type 1 diabetes.

The latest report from the CORONADO study reveals factors predictive of home discharge within 28 days among people with diabetes hospitalized with COVID-19, as well as those linked to mortality risk.

Among people with type 1 diabetes, adding the SGLT2 inhibitor empagliflozin to an automated insulin delivery system may allow replacement of carbohydrate counting with a simple meal announcement, suggest findings from a pilot randomized trial.

Researchers find that older adults with diabetes are frequently treated to an intensive glycemic target, putting them at risk for poor outcomes, particularly when high-risk agents are used.

Increased BMI and insulin resistance are important predictors of diabetic ketoacidosis risk among people with type 1 diabetes using SGLT2 inhibitors, say the authors of a meta-analysis and meta-regression.

Intravitreous aflibercept and vitrectomy with panretinal laser photocoagulation appear to have similar efficacy over 24 weeks when used for the treatment of vitreous hemorrhage from proliferative diabetic retinopathy, researchers report.

Switching to fast-acting insulin aspart significantly improves glycemic control and time in glucose target range in people with type 1 diabetes using continuous glucose monitoring, data from the real-world GoBolus study show.

A device that clips onto an insulin pen can guide people with type 1 diabetes to more effectively rotate their injection site, resulting in less lipohypertrophy and glycemic variability, show the results of a proof-of-concept study.

A fully automated dual-hormone delivery system with pramlintide and faster-acting insulin aspart delivers overall glycemic control that is nearly as good as that achieved with a hybrid closed-loop system with the insulin only, report researchers at the virtual 56th EASD Annual Meeting.

Researchers have demonstrated a sustained safety profile for intraperitoneal insulin infusion with an implantable pump in patients with type 1 diabetes and initially high glucose variability.